Approval · Notice of Compliance 37043 · 2026
ADRUXE: Notice of Compliance 37043
Issued February 13, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37043
- Date
- February 13, 2026
- Company
- Dr Reddy's Laboratories LtdPrinceton, New Jersey, United States
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Canadian reference product
- RITUXAN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ADRUXE | 02565781 | Approved |
Medicinal ingredients
- RITUXIMAB 10 MG per ML